Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

CeNeS grants license to Shire for dopamine D1 agonist program

Dec. 27, 2000

AstraZeneca seeks FDA approval for pediatric indication of Naropin

Dec. 27, 2000

Mitsubishi-Tokyo stops development of antidepressant MCI-225

Dec. 22, 2000

Phenserine enters phase II trial for Alzheimer's disease

Dec. 22, 2000

Conformationally constrained butyrophenones as potential antipsychotic agents

Dec. 22, 2000

Eisai responsible for Japanese development, marketing of botulinum toxin type B

Dec. 22, 2000

Combined 5-HT1A/5-HT2/D2 receptor agonists designed at FAES

Dec. 21, 2000

Tetralone and thienylcyclohexanone derivatives selectively bind to GABA-A alpha5 subunit

Dec. 21, 2000

GABA analogues reported to modulate substance P

Dec. 21, 2000

Questcor arranges Asian marketing agreement for metoclopramide nasal spray

Dec. 21, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...